Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report

doi:10.21037/tlcr-22-288

	Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
	Gu, Xiaodong 4,5,6; Wang, Wenxian 5,6; Wu, Wei 6,7; Zhang, Yiping 5,6; Shao, Lan 5,6; Santarpia, Mariacarmela 8; Christopoulos, Petros 1,2,9,10; Myall, Nathaniel J.3; Shi, Zhiyong 5,6; Lou, Guangyuan 5,6
刊名	TRANSLATIONAL LUNG CANCER RESEARCH
	2022-05-01
卷号	11
关键词	Non-small cell lung cancer (NSCLC) HIVEP1-ALK alectinib intergenic region (IGR) case report
ISSN号	2218-6751
DOI	10.21037/tlcr-22-288
通讯作者	Lou, Guangyuan(lougy@zjcc.org.cn)
英文摘要	Background: Anaplastic lymphoma kinase (ALK) fusion is an important oncogenic driver in non-small cell lung cancer (NSCLC). Reports on the intergenic region (IGR) as an ALK fusion partner are rare. Here, we report the case of a patient with advanced NSCLC harboring a human immunodeficiency virus type I enhancer binding protein 1 (HIVEP1)-ALK fusion that responded effectively to alectinib. Case Description: A 60-year-old non-smoking male was referred with a 3-month history of productive cough secondary to lung adenocarcinoma metastatic to mediastinal lymph nodes, brain, liver, and bone (T2N3M1c, stage IVB). Next-generation sequencing identified an IGR (upstream HIVEP1-) ALK fusion, and immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results were consistent with an ALK-positive tumor. The patient was subsequently started on alectinib, with no obvious adverse reaction. After 1 month of therapy, the patient achieved significantly remission of the clinical symptoms and had led to an ongoing partial response (PR) lasting >33 months. Conclusions: Our experience highlights the efficacy of alectinib in a patient with HIVEP1-ALK fusion positive NSCLC with multiple metastases including brain disease, and the need for multiple genetic testing methods to verify the oncogenicity of ALK fusions prior to treatment. It could provide useful guidance for the treatment of similar cases in the future.
资助项目	Zhejiang Medical and Health Science and Technology Program[2022KY644] ; Zhejiang Medical and Health Science and Technology Program[2018KY023]
WOS关键词	BRAIN METASTASES ; ALK ; CANCER ; SURVIVAL
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	AME PUBLISHING COMPANY
WOS记录号	WOS:000834668600007
资助机构	Zhejiang Medical and Health Science and Technology Program
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129259]
专题	中国科学院合肥物质科学研究院
通讯作者	Lou, Guangyuan
作者单位	1.German Ctr Lung Res DZL, Heidelberg, Germany 2.Translat Lung Res Ctr, Heidelberg, Germany 3.Stanford Canc Inst, Div Oncol, Stanford, CA USA 4.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Med Oncol, 1 Banshan East Rd, Hangzhou 310022, Peoples R China 6.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Peoples R China 8.Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy 9.Heidelberg Univ Hosp, Thoraxklin, Dept Thorac Oncol, Heidelberg, Germany 10.Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany
推荐引用方式 GB/T 7714	Gu, Xiaodong,Wang, Wenxian,Wu, Wei,et al. Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report[J]. TRANSLATIONAL LUNG CANCER RESEARCH,2022,11.
APA	Gu, Xiaodong.,Wang, Wenxian.,Wu, Wei.,Zhang, Yiping.,Shao, Lan.,...&Lou, Guangyuan.(2022).Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.TRANSLATIONAL LUNG CANCER RESEARCH,11.
MLA	Gu, Xiaodong,et al."Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report".TRANSLATIONAL LUNG CANCER RESEARCH 11(2022).